Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Kura Oncology, Inc. (KURA)

Kura Oncology Q2 net loss rises to $68.3 million; KOMZIFTI sales reach $9.1 million

Mixed Impact 3 of 5 earnings Written later

Kura Oncology reported second quarter 2026 results, its second full quarter of KOMZIFTI sales. Total revenue rose to $20.9 million from $15.3 million a year earlier, but the net loss widened to $68.3 million, or $0.77 per share, from $66.1 million, or $0.75 per share. Cash, cash equivalents and short-term investments fell to $519.0 million at June 30, 2026, from $667.2 million at December 31, 2025, and the company cites $180 million in expected collaboration payments from Kyowa Kirin.

Key points

  • Net product revenue was $9.1 million, compared with none in 2Q 2025; new patient starts were about 115, up 35% from 1Q 2026.
  • Collaboration revenue fell to $11.8 million from $15.3 million in 2Q 2025.
  • Net loss was $68.3 million, or $0.77 per share, versus $66.1 million, or $0.75 per share, a year earlier.
  • Cash and short-term investments were $519.0 million at June 30, 2026, plus $180 million in anticipated Kyowa Kirin collaboration payments.

The filing

CompanyKura Oncology, Inc. (KURA)
Form8-K, current report
Filed with the SECAug 12, 2026, 4:10 PM ET
Accession number0001193125-26-346856

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.